| DC12079 |
DMU2105 |
DMU2105 is a potent and specific CYP1B1 inhibitor, with IC50s of 10, 742 nM for CYP1B1 and CYP1A1, respectively. |
|
| DC7404 |
DMXAA
Featured
|
DMXAA (Vadimezan) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM, respectively. Phase 3. |
|
| DC20959 |
DNDI-8219 |
DNDI-8219 is a novel potent, orally active antileishmanial agent with IC50 of 0.19 uM against Leishmania donovani (L. don). |
|
| DC23671 |
DNMDP |
DNMDP is a potent and selective cancer cell cytotoxic agent that binds to PDE3A, promotes an interaction between PDE3A and Schlafen 12 (SLFN12). |
|
| DC11337 |
MMP Substrate II Control |
Dnp-GPLG is a peptide for use as a negative control for activity of matrix metalloproteinases (MMPs) that cleave peptides containing the sequence Dnp-GPLG. |
|
| DC11342 |
MMP-1 Fluorogenic Substrate III |
Dnp-P-Cha-Abu-Cys(Me)-HA-K(Nma)-NH2 is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-9. |
|
| DC11348 |
MMP-1/MMP-9 Fluorogenic Substrate
Featured
|
Dnp-P-Cha-G-Cys(Me)-HA-K(Nma)-NH2 is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-9 |
|
| DC11351 |
MMP-1 Fluorogenic Substrate I
Featured
|
Dnp-PLALWAR is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1) and MMP-8. |
|
| DC11339 |
MMP-8/MMP-26 Fluorogenic Substrate
Featured
|
Dnp-PLAYWAR is a fluorogenic substrate for matrix metalloproteinase-8 (MMP-8) and MMP-26.The activity of MMP-8 and MMP-26 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitro |
|
| DC11347 |
MMP-1 Substrate II
Featured
|
Dnp-PLG-Cys(Me)-HA-DArg-NH2 is a peptide substrate for matrix metalloproteinase-1 (MMP-1).It has an improved kcat/Km ratio compared with the MMP-1 flurogenic substrate Dnp-PLGLWA-DArg-NH2. |
.png)
|
| DC11344 |
MMP-2/MMP-9 Fluorogenic Substrate I |
Dnp-PLGMWSR is a fluorogenic substrate for matrix metalloproteinase-2 (MMP-2) and MMP-9.The activity of MMP-2 and MMP-9 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitroph |
|
| DC11345 |
MMP-7 Fluorogenic Substrate |
Dnp-RPLALWRS is a fluorogenic substrate for matrix metalloproteinase-7 (MMP-7).The activity of MMP-7 can be quantified by measuring tryptophan fluorescence that is unquenched upon peptide hydrolysis that removes the N-terminal dinitrophenol (Dnp) group. |
|
| DC21509 |
DNS-pE |
DNS-pE (PHGDH Fluorescent Probe DNS-pE) is the first small molecule that can selectively label endogenous 3-phosphoglycerate dehydrogenase (PHGDH) from various mammalian cells. |
|
| DC20364 |
DNS-pE2 |
DNS-pE2 is the first small molecule that can selectively label endogenous 3-phosphoglycerate dehydrogenase (PHGDH) from various mammalian cells. |
|
| DC20136 |
DO34 analog |
DO34 analog is a triazole DAGL(α) inhibitor extracted from patent WO2017096315 A1, compound 100. |
|
| DC20960 |
DO-34 |
DO-34 is a highly potent dual DAGLα/β inhibitor with IC50 of 6 nM 3-8 nM, respectively. |
|
| DC8416 |
Docetaxel Trihydrate |
Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules. |
|
| DC4187 |
Docetaxel
Featured
|
Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules through binding to stabilized microtubules. |
|
| DC12208 |
Docosapentaenoic acid 22n-3 |
Docosapentaenoic acid (22n-3) is a component of phospholipids found in all animal cell membranes. |
|
| DC10247 |
Docusate Sodium |
Docusate Sodium is a laxative used to treat constipation, for constipation due to the use of opiates it maybe used with a stimulant laxative, can be taken by mouth or rectally. |
|
| DC12216 |
Dodecanoylcarnitine
Featured
|
Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease. |
|
| DC9588 |
Dofequidar (fumarate) |
Dofequidar fumarate(MS-209 fumarate), an orally active quinoline compound, has been reported to overcome MDR by inhibiting ABCB1/P-gp, ABCC1/MDR-associated protein 1, or both.
|
|
| DC9323 |
Dalasetron (Mesylate hydrate) |
Dolasetron(MDL-73147) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy. |
|
| DC3155 |
Donepezil hydrochloride
Featured
|
Donepezil is a specific and potent AChE inhibitor for bAChE and hAChE with IC50 of 8.12 nM and 11.6 nM , respectively. |
|
| DC11103 |
Tavapadon
Featured
|
Tavapadon is a potent, orally-bioavailable, selective partial agonist of the dopamine D1 and D5 receptors. |
|
| DC9308 |
Doravirine (MK-1439)
Featured
|
Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor. |
|
| DC20365 |
Dorrigocin A |
Dorrigocin A is a natural compound that shows potent antiproliferative effect on tumor cell line.. |
|
| DC4219 |
Dorzolomide hydrochloride |
Dorzolamide HCl is a carbonic anhydrase inhibitor. |
|
| DC20057 |
Dot1L-IN-1 |
Dot1L-IN-1 is a highly potent, selective and structurally novel Dot1L inhibitor with a Ki of 2 pM. |
|
| DC21895 |
DOTA-ADIBO |
DOTA-ADIBO is a Click Chemistry intermidate used for antibody-drug conjugates.. |
|
